OXYGENTA PHARMACEUTICAL
|
OXYGENTA PHARMACEUTICAL Last 5 Year Financial Ratios History
[Standalone]
| Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | -1.04 | -8.15 | -0.43 | 2.87 | -5.67 |
| CEPS(Rs) | -0.24 | -6.70 | 0.69 | 4.04 | -4.69 |
| DPS(Rs) | - | - | - | - | - |
| Book NAV/Share(Rs) | -6.18 | -32.53 | -24.38 | -37.27 | -40.14 |
| Tax Rate(%) | 74.92 | -1.74 | -24.75 | 6.81 | 2.58 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | -24.46 | -22.97 | 2.44 | 7.39 | -57.36 |
| EBIT Margin(%) | -30.97 | -31.90 | 0.72 | 9.47 | -35.34 |
| Pre Tax Margin(%) | -34.99 | -36.70 | -0.81 | 6.04 | -43.31 |
| PAT Margin (%) | -8.78 | -37.34 | -1.01 | 5.63 | -42.20 |
| Cash Profit Margin (%) | -2.06 | -30.72 | 1.62 | 7.93 | -34.92 |
| Performance Ratios | |||||
| ROA(%) | -6.40 | -27.09 | -1.88 | 11.16 | -29.10 |
| ROE(%) | - | - | - | - | - |
| ROCE(%) | -41.69 | -50.32 | 3.18 | - | - |
| Asset Turnover(x) | 0.73 | 0.73 | 1.86 | 1.98 | 0.69 |
| Sales/Fixed Asset(x) | 0.82 | 0.75 | 1.79 | 1.85 | 0.55 |
| Working Capital/Sales(x) | -4.13 | -3.93 | 40.46 | -33.50 | -1.51 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 1.22 | 1.34 | 0.56 | 0.54 | 1.81 |
| Receivable days | 80.66 | 69.12 | 9.61 | 7.13 | 12.49 |
| Inventory Days | 117.03 | 111.83 | 58.49 | 57.41 | 127.53 |
| Payable days | 254.01 | 229.85 | 78.25 | 109.07 | 199.77 |
| Valuation Parameters | |||||
| PER(x) | - | - | - | - | - |
| PCE(x) | -118.58 | -5.46 | 34.82 | - | - |
| Price/Book(x) | -4.69 | -1.13 | -0.99 | - | - |
| Yield(%) | - | - | - | - | - |
| EV/Net Sales(x) | 3.89 | 3.87 | 1.42 | 1.11 | 2.70 |
| EV/Core EBITDA(x) | -15.97 | -16.88 | 58.17 | 14.65 | -4.72 |
| EV/EBIT(x) | -12.56 | -12.13 | 197.73 | 11.70 | -7.63 |
| EV/CE(x) | 4.16 | 5.50 | 2.76 | 1.70 | 1.99 |
| M Cap / Sales | 2.45 | 1.68 | 0.56 | - | - |
| Growth Ratio | |||||
| Net Sales Growth(%) | 27.93 | -48.80 | 16.33 | 279.30 | -33.12 |
| Core EBITDA Growth(%) | -35.99 | -579.49 | -62.36 | 150.21 | -353.26 |
| EBIT Growth(%) | -24.20 | -2,369.43 | -91.16 | 201.63 | -76.47 |
| PAT Growth(%) | 69.93 | -1,795.44 | -120.84 | 150.62 | -77.87 |
| EPS Growth(%) | 87.25 | -1,795.29 | -114.97 | 150.62 | -77.87 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | -2.77 | -1.47 | -1.51 | -1.26 | -0.66 |
| Current Ratio(x) | 0.72 | 0.76 | 1.19 | 0.91 | 0.43 |
| Quick Ratio(x) | 0.31 | 0.40 | 0.28 | 0.22 | 0.16 |
| Interest Cover(x) | -7.70 | -6.65 | 0.47 | 2.76 | -4.43 |
| Total Debt/Mcap(x) | 0.59 | 1.31 | 1.53 | - | - |
Compare Financial Ratios of peers of OXYGENTA PHARMACEUTICAL
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| OXYGENTA PHARMACEUTICAL | ₹284.9 Cr | 2.9% | -5% | 88.5% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹418,468.0 Cr | 3.4% | 2.2% | 13.6% | Stock Analytics | |
| DIVIS LABORATORIES | ₹156,319.0 Cr | 5.3% | 3.9% | 51.8% | Stock Analytics | |
| CIPLA | ₹122,075.0 Cr | 3.3% | 1.2% | 9.7% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹110,125.0 Cr | 4% | 6.3% | 29.2% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹98,227.9 Cr | 6.1% | 2.3% | -3.2% | Stock Analytics | |
OXYGENTA PHARMACEUTICAL Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| OXYGENTA PHARMACEUTICAL | 2.9% |
-5% |
88.5% |
| SENSEX | 7.5% |
7.6% |
7% |
You may also like the below Video Courses
